|
Product Disclosures Reflecting standard oncology practice, which often requires the off-label or investigational use of some products, this educational activity includes information about many drugs. All faculty participating in continuing education activities are expected to disclose the approved or investigational status (related to the subject matter of this activity—breast cancer) of all products and devices under discussion. This information, as of the time of printing, is summarized briefly below.* In addition, primary references and full prescribing information should be consulted for complete information. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgment and accepted standards of care. The following drugs discussed in the text are FDA approved for the treatment of breast cancer: cyclophosphamide (Cytoxan, Neosar), doxorubicin (Adriamycin), tamoxifen (Nolvadex), and trastuzumab (Herceptin). The following drugs discussed in the text are FDA approved for other uses: granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine, Prokine]), interferon, and progesterone (Prometrium). The following drugs discussed in the text are investigational in the United States: avipox-CEA, DETOX (monophosphoryl lipid A and mycobacteria cell skeleton), MUC-1 cDNA, MUC-1 STn, rF-CEA-TRICOM, rV-CEA, STn-KLH (Theratope), vaccinia MUC-1.
|